HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS

HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS

The present invention claims high dose CD20 antibody subcutaneous formulations together with hyaluronidase. Preferred antibodies are MabThera, Ocrelizumab and GA101, preferably in a dose of 120 mg/ml. The preferred hyaluronidase is Halozyme.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Adler, Michael, Mahler, Hanns-Christian, Stauch, Oliver Boris
Format: Patent
Sprache:hrv ; eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Adler, Michael
Mahler, Hanns-Christian
Stauch, Oliver Boris
description The present invention claims high dose CD20 antibody subcutaneous formulations together with hyaluronidase. Preferred antibodies are MabThera, Ocrelizumab and GA101, preferably in a dose of 120 mg/ml. The preferred hyaluronidase is Halozyme.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_HRP20231019TT1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>HRP20231019TT1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_HRP20231019TT13</originalsourceid><addsrcrecordid>eNrjZND38HT38IlUcPb3c3b1CwlyDHF1UQjwcAzydXR2DQ3xdHb0UXDzD_IN9XEM8fT3C-ZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfEeQQFGBkbGhgaGliEhhsbEqQIA0gknxQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS</title><source>esp@cenet</source><creator>Adler, Michael ; Mahler, Hanns-Christian ; Stauch, Oliver Boris</creator><creatorcontrib>Adler, Michael ; Mahler, Hanns-Christian ; Stauch, Oliver Boris</creatorcontrib><description>The present invention claims high dose CD20 antibody subcutaneous formulations together with hyaluronidase. Preferred antibodies are MabThera, Ocrelizumab and GA101, preferably in a dose of 120 mg/ml. The preferred hyaluronidase is Halozyme.</description><language>hrv ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231208&amp;DB=EPODOC&amp;CC=HR&amp;NR=P20231019T1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231208&amp;DB=EPODOC&amp;CC=HR&amp;NR=P20231019T1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Adler, Michael</creatorcontrib><creatorcontrib>Mahler, Hanns-Christian</creatorcontrib><creatorcontrib>Stauch, Oliver Boris</creatorcontrib><title>HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS</title><description>The present invention claims high dose CD20 antibody subcutaneous formulations together with hyaluronidase. Preferred antibodies are MabThera, Ocrelizumab and GA101, preferably in a dose of 120 mg/ml. The preferred hyaluronidase is Halozyme.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZND38HT38IlUcPb3c3b1CwlyDHF1UQjwcAzydXR2DQ3xdHb0UXDzD_IN9XEM8fT3C-ZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfEeQQFGBkbGhgaGliEhhsbEqQIA0gknxQ</recordid><startdate>20231208</startdate><enddate>20231208</enddate><creator>Adler, Michael</creator><creator>Mahler, Hanns-Christian</creator><creator>Stauch, Oliver Boris</creator><scope>EVB</scope></search><sort><creationdate>20231208</creationdate><title>HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS</title><author>Adler, Michael ; Mahler, Hanns-Christian ; Stauch, Oliver Boris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_HRP20231019TT13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>hrv ; eng</language><creationdate>2023</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Adler, Michael</creatorcontrib><creatorcontrib>Mahler, Hanns-Christian</creatorcontrib><creatorcontrib>Stauch, Oliver Boris</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Adler, Michael</au><au>Mahler, Hanns-Christian</au><au>Stauch, Oliver Boris</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS</title><date>2023-12-08</date><risdate>2023</risdate><abstract>The present invention claims high dose CD20 antibody subcutaneous formulations together with hyaluronidase. Preferred antibodies are MabThera, Ocrelizumab and GA101, preferably in a dose of 120 mg/ml. The preferred hyaluronidase is Halozyme.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language hrv ; eng
recordid cdi_epo_espacenet_HRP20231019TT1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T09%3A30%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Adler,%20Michael&rft.date=2023-12-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EHRP20231019TT1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true